A global resurgence of measles has been driven by declining vaccination coverage and gaps in herd immunity, renewing interest in antibody-based therapeutic strategies targeting measles virus (MeV). Recent studies demonstrate rapid advances in the identification, structural characterization, and functional evaluation of monoclonal antibodies (mAbs) directed against key viral glycoproteins.
A recent study by researchers from La Jolla Institute for Immunology has produced a panel of human monoclonal antibodies (mAbs) specific for MeV hemagglutinin (H) and fusion (F) surface proteins. Human monoclonal antibodies isolated from vaccinated individuals recognize multiple discrete epitope clusters (four on H and five on F) distributed across structurally and functionally distinct regions of the viral entry machinery. These antibodies exhibit broad reactivity across circulating MeV genotypes and achieve exceptionally high neutralization potency, with several demonstrating picomolar inhibitory activity.
Thus, these highly potent human antibodies can target measles in multiple ways, offering promising new options to prevent or treat the disease.
Recent studies also show that antibodies can stop measles virus in several different ways rather than through a single mechanism. Antibodies that target the hemagglutinin (H) protein mainly prevent the virus from attaching to human cells by blocking its interaction with specific cell-surface receptors (proteins the virus uses to gain entry), such as SLAMF1 and nectin-4, thereby stopping infection before it begins. In contrast, antibodies against the fusion (F) protein act at later stages by interfering with the shape changes (conformational dynamics) the virus needs to merge with the host cell membrane.
Some antibodies “lock” the F protein in its prefusion state, making it harder for the virus to initiate fusion, while others block intermediate steps in this process, preventing the protein from completing the structural rearrangements required for entry. Interestingly, some antibodies trigger the F protein too early but then prevent it from finishing the process, effectively causing a failed attempt at cell entry. Together, these findings show that antibody neutralization involves multiple strategies targeting different steps of viral entry, rather than a single uniform mode of action.
The way these antibodies function suggests they could be used both to prevent infection (prophylactic use) and to treat infection after exposure (therapeutic use). Studies in animal models show that certain antibodies targeting the H and F proteins can greatly reduce the viral load, in some cases almost completely stopping the infection. Notably, these antibodies can still be effective even when given after exposure to the virus, which is important for real-world situations where treatment begins after infection has already started. This is especially relevant because there are currently no approved antiviral drugs for measles, and existing post-exposure treatments rely on polyclonal immunoglobulin (a mixture of many different antibodies from donors), which can vary in effectiveness.
In addition, researchers have identified antibodies that work in different ways and bind to different parts of the virus (non-overlapping epitopes), supporting the idea of using antibody cocktails, which are combinations of antibodies, to improve effectiveness and reduce the chance that the virus can develop resistance.
Despite their promise, a recent perspective warns how monoclonal antibody therapies may introduce important risks related to viral evolution. Vaccination typically produces a polyclonal immune response, meaning the body generates many different antibodies that target multiple epitopes at the same time. This makes it very difficult for the virus to escape through mutation. In contrast, mAbs are designed to bind to a single specific epitope, which makes them more vulnerable to viral escape, where a small genetic change (point mutation) allows the virus to avoid being recognized.
A key concern is that the regions targeted by these therapeutic antibodies often overlap with those targeted by natural or vaccine-induced immunity. This raises the possibility that mutations selected in response to antibody therapy could also weaken the protection provided by vaccines. Modeling studies suggest that while measles virus currently requires multiple simultaneous mutations to evade vaccine immunity, the emergence of intermediate “escape” mutations under antibody pressure could lower this barrier, making it easier for vaccine-resistant strains to arise. This would represent a major change for measles virus, which has historically remained antigenically stable under decades of widespread vaccination.
The challenge ahead is to integrate antibody therapeutics into measles control without weakening the durability of vaccine-induced immunity. This will depend on thoughtful choices around epitope targets, antibody combinations, and how these therapies interact with existing immunity, so that new treatments can support one of the most successful vaccination programs in modern medicine.
Biointron’s Q1 2026 Antibody Industry Trends report aims to explore the events a……
Bispecific antibody-drug conjugates, or BsADCs, combines the payload-delivery fu……
Programmable antibodies can describe several related approaches that make antibo……
Chemical conjugation is the process of using defined chemical reactions to attac……
You can also contact us on the Scientist and Science Exchange marketplaces.
